Favipiravir在印度的销售激增，针对的是轻度COVID-19病例
医生正在为轻度COVID-19的患者开出越来越多的基于favipiravir的药物
因为它实际上在9月份成为印度最畅销的药物，其本地生产的产品的销售额不到2000万美元（美国）。
国产品牌
自6月份推出以来，销售迅速，当然，随着COVID-19感染的蔓延。
数据
来自IMS IQVIA和所有印度血统化学家与分销商（AIOCD）。
Favipiravir Boom in India：
TrialSite reported on a number of different generic pharma company initiatives to develop and private label favipiravir products.
The Economic Times in India now reports 10 favipiravir-based brands in India, led in sales by Glenmark’s FabiFlu followed by Ciplan and Lupin.
Intense competition of course has led price declines in bids for position and market share. Prices have been cut to Rs 30 per tablet or about 41 cents per tablet.
https://www.trialsitenews.com/favipiravir-sales-skyrocket-in-india-targeting-mild-covid-19-cases/